Aligos Therapeutics Inc Revenue Growth Rates (ALGS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aligos Therapeutics Inc   (NASDAQ: ALGS)
 

ALGS's Revenue Growth by Quarter and Year

Aligos Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALGS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 27.78
1st Quarter March 2.83
FY 30.61

ALGSs Annual Revenue
Aligos Therapeutics Inc 's Revenue in the fiscal year 2025 $ 2.19 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2024 $ 3.95 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2023 $ 15.53 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2022 $ 13.91 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2021 $ 4.36 millions




ALGS Revenue second quarter 2026 Y/Y Growth Comment
Aligos Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue surge of 2763.71% year on year, to $ 27.78 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue growth. While Aligos Therapeutics Inc ' s Revenue doubling of 2763.71% ranks overall at the positon no. 2864 in the second quarter 2026.


ALGS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -73.02 % -76.49 % -24.29 %
3rd Quarter September - -41.73 % -60.8 % -21.17 %
2nd Quarter June 2763.71 % -8.49 % -84.62 % 86.72 %
1st Quarter March 812.9 % -68.69 % -63.6 % 5.84 %
FY   - -44.56 % -74.57 % -

Financial Statements
Aligos Therapeutics Inc 's second quarter 2026 Revenue $ 27.78 millions ALGS's Income Statement
Aligos Therapeutics Inc 's second quarter 2025 Revenue $ 0.97 millions Quarterly ALGS's Income Statement


ALGS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -77.03 % -50.39 % -17.28 %
3rd Quarter September - -23.71 % 19.81 % -52.98 %
2nd Quarter June 881.55 % 212.9 % 7.07 % 153.31 %
1st Quarter March 1564.71 % -50.79 % -63.06 % -23.16 %
FY (Year on Year)   - -44.56 % -74.57 % -


Back to ALGS Growth rate Comparisons >> Back to ALGS Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #406
Overall #2864

Revenue Y/Y Growth Statistics
High Average Low
893.01 % 68.95 % -76.29 %
(Jun 30 2026)   (Mar 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #406
Overall #2864
Revenue Y/Y Growth Statistics
High Average Low
893.01 % 68.95 % -76.29 %
(Jun 30 2026)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aligos Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1574.56 % 148.73 % -77.19 %
(Mar 31 2026)  


ALGS's II. Quarter Q/Q Revenue Comment
Aligos Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 881.55%, to $ 27.78 millions, from $2.83 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Aligos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 33.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #12
Overall #33
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #12
Overall #33
Revenue Q/Q Growth Statistics
High Average Low
1574.56 % 148.73 % -77.19 %
(Mar 31 2026)  


ALGS's II. Quarter Q/Q Revenue Comment
Aligos Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 881.55%, to $ 27.78 millions, from $2.83 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Aligos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 33.


Aligos Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 31.52 $ 4.71 $ 2.19 $ 2.65 $ 3.17
Y / Y Revenue Growth (TTM) 893.01 % 43.88 % -44.59 % -55.88 % -60.16 %
Year on Year Revenue Growth Overall Ranking # 3646 # 2051 # 3260 # 2605 # 3006
Seqeuential Revenue Change (TTM) 569.88 % 115.23 % -17.38 % -16.64 % -2.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 2864 # 3183 # 3127 # 2847 # 3120


Cumulative Revenue growth Comment
With 893.01% annual Revenue growth, Aligos Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 511 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2051 to 3646.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 512
Overall # 3646

Revenue TTM Y/Y Growth Statistics
High Average Low
893.01 %
 68.95 %
-76.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 406
S&P 500 # 2864
Cumulative Revenue growth Comment
With 893.01% annual Revenue growth, Aligos Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 511 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2051 to 3646.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 512
Overall # 3646

Revenue TTM Y/Y Growth Statistics
High Average Low
893.01 %
68.95 %
-76.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 406
S&P 500 # 2864




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALGS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Hcw Biologics Inc 3,828.21%$ 3,828.214 millions
Protagonist Therapeutics inc 3,749.17%$ 3,749.171 millions
Aligos Therapeutics Inc 2,778.55%$ 2,778.549 millions
Crinetics Pharmaceuticals Inc 2,336.28%$ 2,336.275 millions
Tao Synergies Inc 2,136.90%$ 2,136.901 millions
Liquidia Corporation1,842.73%$ 1,842.729 millions
Verastem Inc 1,775.43%$ 1,775.433 millions
EBR Systems, Inc.1,453.92%$ 1,453.919 millions


About Aligos Therapeutics Inc Revenue Growth Rates (ALGS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aligos Therapeutics Inc (CIK 1799448).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-336851
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aligos Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.